Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | RBP4 | P02753 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375425 | 0.81 | EPHX2 (0.68) | HSD11B1EPHX2RBP4GAAMAPT | |
| SCHEMBL4395581 | 0.80 | HSD11B1 (0.62) | HSD11B1EPHX2RBP4GAANPC1 | |
| SCHEMBL11153275 | 0.80 | HTR1A (0.55) | — | |
| SCHEMBL22668886 | 0.79 | EPHX2 (0.73) | HSD11B1EPHX2RBP4GAAMAPT | |
| SCHEMBL4402731 | 0.78 | DRD4 (0.54) | HSD11B1 | |
| SCHEMBL16689587 | 0.78 | HSD11B1 (0.62) | HSD11B1EPHX2MAPTTSHR | |
| SCHEMBL1375423 | 0.78 | EPHX2 (0.68) | HSD11B1EPHX2RBP4GAAMAPT | |
| Hydrochloric Acid SCHEMBL1375801 | 0.77 | HSD11B1 (0.65) | HSD11B1EPHX2RBP4GAA | |
| SCHEMBL22669112 | 0.77 | EPHX2 (0.71) | HSD11B1EPHX2RBP4GAAMAPT | |
| SCHEMBL16689555 | 0.77 | HSD11B1 (0.61) | HSD11B1EPHX2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | claimed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | claimed |
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | disclosed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | disclosed |
| EP-1971600-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK Holdings Co., Ltd. (KR) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007078113-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | HSD11B1 417/4885EPHX2 2685/4885RBP4 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.